Form 4: Aura Biosciences CFO Julie Feder Executes Stock Options and Sells Shares Under 10b5-1 Plan

Julie Feder, CFO of Aura Biosciences, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Julie Feder, the Chief Financial Officer of Aura Biosciences, executed stock options and sold shares of common stock on October 18, 2024.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on June 23, 2023.
• Feder exercised options to acquire 17,500 shares at $2.74, 2,631 shares at $4.25, and 5,000 shares at $5.48.
• She then sold 25,131 shares at a weighted average price of $12.0314, with individual sales ranging from $12.0000 to $12.3000.
• Following these transactions, Feder directly owns 134,276 shares of Aura Biosciences common stock.
• She also holds options to purchase 68,257 shares at $2.74, 32,359 shares at $4.25, and 120,547 shares at $5.48.
• A power of attorney was executed on October 21, 2024, appointing Conor Kilroy and Amy Elazzouzi to act on Feder's behalf for Section 16 filings.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects routine transactions under a pre-arranged trading plan, with no indication of positive or negative outlook.

Future Outlook

NA

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares over time while avoiding accusations of trading on non-public information.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading.
• The use of 10b5-1 trading plans is a common strategy among executives to diversify their holdings and manage personal finances while adhering to regulatory requirements.
• Comparable companies such as Allogene Therapeutics, Inc. and Iovance Biotherapeutics, Inc. also have frequent Form 4 filings related to stock option exercises and sales by their executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by a key executive, but the pre-arranged nature of the 10b5-1 plan mitigates concerns about insider trading.

Key Dates